


2026 TIPA International Symposium: Strategy of Market Positioning and Patent Protection in Pharmaceutical Industry Under the Shifting International Order

【Map and Directions】 No.1, Sec. 4, Roosevelt Road, Taipei City, Taiwan <https://reurl.cc/Orpqbr>



研討會簡介

美國川普總統上任後推行「最惠國藥價政策」(MFN)，新近更宣布將大幅提高進口學名藥關稅；全球藥品供應鏈亦應一觸即發的戰爭而受到影響。近年來劇烈變動的國際情勢，為全球製藥產業及各國政府用藥、藥價政策帶來重大挑戰，不僅是受到專利權保護的新藥，甚而是學名藥，均因美國市場變化而會受到影響，包括研發投入、專利布局或全球藥品上市策略。

在 MFN 政策下，OECD 國家的藥品價格會直接影響到美國藥價，因此，跨國藥廠不得不調整或延後在歐洲及其他國家的新藥上市計劃，抑或要求各該國家提高藥品價格（諸如健保藥價），抑或是透過藥品給付協議（managed entry agreement, MEA）或類似協議方式，以確保他國藥品價格不會影響到美國藥價。另外，全球藥品市場過往高度依賴亞洲或特定區域的委託開發製造服務（CDMO）、原料藥（API）與學名藥供應鏈，在國際變局下可能被迫拆解。藥品上市時程及市場消長、供應鏈調整，不僅衝擊民眾藥物取得，亦直接影響製藥產業之研發誘因、研發投入及專利布局。

美國政策及國際變局對臺灣有各層面的衝擊，全民健康保險之藥品核價（諸如給付協議 MEA）直接影響新藥在臺灣上市時程與專利布局需求。關稅壁壘增加藥物海外市場之不確定性，同樣會衝擊政府近年來推動的製藥產業韌性及 CDMO 政策，亦影響本土原料藥及製藥產業之國際市場布局。綜觀全球藥品市場，臺灣之市場規模小，健保核定新藥價格若不高或給付協議之運作有疑義，在美國 MFN 政策下必然影響新藥在臺上市時程及延後，進而直接衝擊公共衛生政策落實，亦阻礙新藥藥廠在臺尋求專利權保護及專利布局之需求與意願。對於本土製藥產業及學名藥藥廠而言，亦會因為健保藥價偏低而受到影響，難有意願尋求轉型及研發新藥，抑或提高學名藥品質。因此，國際變局及國內健保藥品市場擠壓，會滿足內國用藥需求及國民健康。

主辦單位很榮幸有機會邀請美歐嫺熟製藥產業的律師事務，包括 Finnegan 及 Hogan Lovells Cadwalader 律師事務所，由嫺熟藥品上市與專利布局的律師，分享國際變局對全球製藥產業之影響，尤其是歐洲國家政府及產業如何因應。在臺灣方面，很榮幸邀請到新藥及學名藥產業代表、實務律師、法官及各界專家，共同討論國際變局對於臺灣藥品上市、藥品韌性、CDMO 政策落實、專利布局及本土製藥產業之落實與影響。

Introduction

In 2025 the U.S. government introduced the "Most Favored Nation" (MFN) drug pricing policy and has recently announced plans to substantially increase tariffs on imported generic medicines. At the same time, the threat of escalating geopolitical conflicts has further disrupted the global pharmaceutical supply chain. Together, these developments illustrate how rapidly evolving international conditions have created unprecedented challenges for the pharmaceutical industry. These impacts extend beyond innovative medicines to generic drugs, reshaping the U.S. market and influencing pharmaceutical companies' R&D investment decisions, patent strategies, manufacturing and supply chain planning, and global launch sequencing.

Under the MFN policy, drug prices in OECD countries directly influence U.S. drug prices. As a result, multinational pharmaceutical companies may postpone or adjust new product launches in Europe and other markets, seek higher reimbursement prices from national healthcare systems, or rely on managed entry agreements (MEAs) and other pricing mechanisms to minimize the impact of ex-U.S. pricing on the U.S. market. Meanwhile, the global pharmaceutical industry has long depended on contract development and manufacturing organizations (CDMOs), active pharmaceutical ingredient (API) production, and generic drug supply chains concentrated in Asia and a limited number of manufacturing hubs. In the face of shifting geopolitical conditions, these highly integrated supply chains are increasingly vulnerable to fragmentation and restructuring. Changes in launch timing, market dynamics,

and supply chain configuration not only affect patient access to medicines but also influence pharmaceutical companies' R&D incentives, investment priorities, and global patent portfolio strategies.

These policies and geopolitical developments also have significant implications for Taiwan. Taiwan's National Health Insurance (NHI) drug pricing and reimbursement system directly affects the timing of new drug launches and shapes pharmaceutical companies' patent filing and commercialization strategies in the Taiwanese market. Rising tariff barriers further increase uncertainty for pharmaceutical exports, with potential consequences for the government's efforts to promote the CDMO (contract development and manufacturing organization) industry and strengthen the international competitiveness of Taiwan's API and pharmaceutical manufacturing industries. Given Taiwan's relatively small market share and comparatively lower drug prices, the effects of the U.S. MFN policy may be even more pronounced. Delayed launches of innovative medicines could hinder the implementation of public health initiatives while reducing incentives for pharmaceutical companies to invest in commercialization and patent protection in Taiwan. At the same time, enhancing the resilience and competitiveness of Taiwan's generic drug industry and ensuring a stable domestic medicine supply have become increasingly important to safeguarding national healthcare.

We have this honor to invite distinguished experts from leading U.S. and European law firms with extensive experience in the pharmaceutical sector, including Finnegan and Hogan Lovells. The attorneys, who specialize in pharmaceutical commercialization, intellectual property, and patent portfolio management, will share their perspectives on how evolving international policies are reshaping the global pharmaceutical landscape. This symposium will also feature representatives from Taiwan's innovative and generic pharmaceutical industries, legal practitioners, members of the judiciary, and experts from academia and government. Together, they will explore the implications of these global developments for drug launches in Taiwan, pharmaceutical supply chain resilience, the implementation of Taiwan's CDMO strategy, patent portfolio, and the future competitiveness of Taiwan's pharmaceutical industry.

2026 TIPA 國際研討會：國際變局下之醫藥上市及專利布局與因應

2026 TIPA International Symposium: Strategy of Market Positioning and Patent Protection in Pharmaceutical Industry Under the Shifting International Order

2026 年 10 月 30 日(星期五) 14:00-17:40 | Friday, October 30, 2026 | 14:00-17:40

※本研討會備有中英文同步翻譯

Simultaneous interpretation between Chinese and English will be available.

時間 Time	主題 Subject	主持人 Moderator / 報告人 Speaker/ 與談人 Discussant
13:30-14:00	報到 (30 mins.)	
第一場 Session 1 14:00-15:05 (65 mins.)	醫藥專利權及美國藥價改革影響之新近發展及臺灣現況 Recent Developments in Pharmaceutical Patent and Impacts of US Drug Price Reforms in the USA	【主持人 Moderators】(5 mins.) 廖承威局長，經濟部智慧財產局 Cheng-Wei Liao, Director General, Intellectual Property Office, Ministry of Economic Affairs 【報告人 Speaker】(30 mins. each) (1) Yieyie Yang, Finnegan, Henderson, Farabow, Garrett & Dunner LLP (Washington D.C. Office) 楊燁燁合夥律師，飛翰外國法律事務所 華盛頓特區辦公室 (2) 張哲倫合夥律師，理律法律事務所 Roger Chang, Partner, LEE AND LI Attorneys-at-Law
15:05-15:15	茶歇 Coffee Break (10 mins.)	
第二場 Session 4 15:15-17:25 (130 mins.)	圓桌論壇： 國際變局對於全球醫藥專利權保護、專利布局及製藥產業之影響 Roundtable Discussion: Impacts of Global Changes on Pharmaceutical Patent Protection, Patent Strategy and the Pharma Industry	【主持人 Moderator】(5 mins) 李素華教授，國立臺灣大學法律學院、藥學系合聘教授 / 智慧財產培訓學院計畫共同主持人 Su-Hua Lee, Professor, College of Law/Department of Pharmay, National Taiwan University/Co- PI, TIPA Research Project 【引言報告 Keynote Speech】(25 mins.) Dr. Andreas von Falck, Partner, Hogan Lovells Cadwalader 歐洲面對國際變局之醫藥專利權保護及專利布局之新近發展 Recent Developments in Pharmaceutical Patent Protection and Enforcement in Europe Amidst International Global Changes 【與談人 Discussants】(12 mins. each) (1) 汪漢卿庭長，智慧財產及商業法院 Jack H.C. Wang, Division-Chief Judge, Intellectual Property and Commercial Court

		(1) 黃育文組長，衛生福利部中央健康保險署醫審及藥材組 Yu-Wen Huang, Director, Medical Review and Pharmaceutical Benefits Division, National Health Insurance Administration, Ministry of Health and Welfare (2) 衛生福利部食品藥物管理署代表 (TBC) Taiwan Food and Drug Administration, Ministry of Health and Welfare (TBC) (3) 李克文主任委員，中華民國開發性製藥研究協會 (IRPMA) 法律諮詢小組 James Lee, Chairperson, Legal and Regulatory Joint Working Group, International Research-Based Pharmaceutical Manufacturers Association (4) 陳誼芬理事長，社團法人中華民國學名藥協會 (TGPA) Tiffany Chen, President, Taiwan Generic Pharmaceutical Association (TGPA) (5) 呂紹凡合夥律師，萬國法律事務所 Frank, Shao-Fan Lu, Partner, Formosa Transnational Attorneys-at-Law (6) 張濱璿法務長，聯新國際醫院 Brian Chang, General Counsel, Landseed International Hospital (7) Yieyie Yang, Finnegan, Henderson, Farabow, Garrett & Dunner LLP (Washington D.C. Office) 楊燁燁合夥律師，飛翰外國法律事務所 華盛頓特區辦公室
17:25-17:35	Q&A (10 mins.)	
17:35-17:40	閉幕 Closing Remark	廖承威局長，經濟部智慧財產局 Cheng-Wei Liao, Director General, Intellectual Property Office, Ministry of Economic Affairs 李素華教授，國立臺灣大學法律學院、藥學系合聘教授 / 智慧財產培訓學院計畫共同主持人 Su-Hua Lee, Professor, College of Law/Department of Pharmay, National Taiwan University/Co- PI, TIPA Research Project